NSE: CAMLINFINE | BSE: 532834

Expensive Underperformer

Download real time

155.52 0.76 (0.49%)

53.34% Fall from 52W High

224.1K NSE+BSE Volume

NSE 19 Dec, 2025 3:31 PM (IST)

2,987.3

Market Cap

Above industry Median

Beta 1Year

Very High Volatility

Camlin Fine Sciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CAMLINFINE, BSE:532834 Camlin Fine Sciences Ltd.

Camlin Fine Sciences Ltd.

15 Feb 2023

155.52

0.49%

Result Update:Camlin Fine

Buy: Camlin Fine Sciences Ltd.

Target

Axis Direct

Consequently, we have revised our TP to Rs 180 implying a upside of 21.6% from CMP Rs 148 and Maintain our BUY rating on stock.

Camlin Fine Sciences.. has an average target of 195.00 from 1 broker.

Camlin Fine Sciences Ltd.

16 Nov 2022

155.52

0.49%

Result Update:Camlin Fine

Buy: Camlin Fine Sciences Ltd.

Target

Axis Direct

We maintain our Buy rating on the stock with TP of Rs 190/share valuing the company at 18x its FY24 earnings.

Camlin Fine Sciences.. has an average target of 195.00 from 1 broker.

Camlin Fine Sciences Ltd.

19 Sep 2022, 12:00AM

155.52

0.49%

Pick of the Week:19 SEP 2022

Buy: Camlin Fine Sciences Ltd.

Target

Axis Direct

We recommend a BUY rating on the stock with a near term TP of Rs 147, implying an upside of 14% from CMP.

Camlin Fine Sciences Ltd. is trading below all available SMAs

Camlin Fine Sciences Ltd.

20 Sep 2021, 12:00AM

155.52

0.49%

Axis Annual Analysis:Camlin Fine

Buy: Camlin Fine Sciences Ltd.

Axis Direct

e maintain a BUY rating on the stock with an unchanged TP of Rs 215/share valuing the stock at 17x FY24E EPS.

Camlin Fine Sciences.. has an average target of 195.00 from 1 broker.

Camlin Fine Sciences Ltd.

01 Jun 2021

155.52

0.49%

Result Update:Camlin Fine

Buy: Camlin Fine Sciences Ltd.

Target

Axis Direct

Owing to the strong growth guidance over FY21-23E our estimates undergo a revision leading to a revised TP to Rs. 215/share (Rs. 184/share earlier) and multiple of 18x on its FY23E EPS.

Camlin Fine Sciences has lost -31.82% in the last 3 Months

Camlin Fine Sciences Ltd.

17 May 2021

155.52

0.49%

Result Update:Camlin Fine

Buy: Camlin Fine Sciences Ltd.

Target

Axis Direct

We maintain our BUY recommendation on CFS and value the stock at 16x FY23E EPS to arrive at a TP of Rs. 184/share, implying an upside of 12% from CMP.

Camlin Fine Sciences has gained 28.73% in the last 1 Year

Camlin Fine Sciences Ltd.

19 Feb 2021, 12:00AM

155.52

0.49%

Result Update:Camlin Fine

Buy: Camlin Fine Sciences Ltd.

Axis Direct

We initiate coverage on Camlin Fine Sciences Ltd. (CFS) with a BUY recommendation and a Target Price of Rs. 155, which implies a 46% upside from current levels.

Camlin Fine Sciences.. has an average target of 195.00 from 1 broker.

Camlin Fine Sciences Ltd.

12 Feb 2019

155.52

0.49%

Camlin Fine Sciences' (CFIN) Q3FY19 consolidated performance was above estimates on reven...

Buy: Camlin Fine Sciences Ltd.

Target

Emkay

Refer to important disclosures at the end of this report Going in right direction; maintain Buy Camlin Fine Sciences' (CFIN) Q3FY19 consolidated performance was above estimates on revenue and PAT front. Revenue up 17% yoy to Rs2.41bn (est. Rs2.29bn); EBITDA up 232% yoy to Rs154mn (est. Rs160mn); with net loss at Rs20mn (est. Rs36mn loss). CFIN's performance is headed in the right direction and well in line with our expectations. The key loss-making subsidiaries in Brazil and China are reaching a breakeven. Further,...

Camlin Fine Sciences has lost -48.53% in the last 6 Months

Camlin Fine Sciences Ltd.

17 Feb 2018

155.52

0.49%

Camlin Fine Sciences' (CFIN) consolidated revenue grew by 54% yoy to Rs2.06bn (Emkay Est....

Buy: Camlin Fine Sciences Ltd.

Emkay

Camlin Fine Sciences' (CFIN) consolidated revenue grew by 54% yoy to Rs2.06bn (Emkay Est. Rs1.97bn) on the back of strong growth traction across key segments like Aroma (698% yoy), Blends (59% yoy), Performance (19% yoy) and Shelf-life (6% yoy). EBITDA stood at Rs46mn, up by 130% yoy but was lower than our estimate of Rs98mn on account of exceptional loss of Rs108mn (Loss: Forex -Rs57mn, China JV -Rs50mn)....